



## Clinical trial results:

### Feasibility and Efficacy of dose adjusted Melphalan – Prednisone – Bortezomib (MPV)

### in elderly patients 75 years of age with newly diagnosed Multiple Myeloma; a nonrandomised phase II study

#### Summary

EudraCT number	2013-000320-33
Trial protocol	NL
Global end of trial date	29 June 2022

#### Results information

Result version number	v1 (current)
This version publication date	06 June 2024
First version publication date	06 June 2024

#### Trial information

##### Trial identification

Sponsor protocol code	HOVON_123_MM
-----------------------	--------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	HOVON
Sponsor organisation address	De Boelelaan 1117, Amsterdam, Netherlands,
Public contact	HOVON Data Center, HOVON, +31 (0)107041560, hdc@erasmusmc.nl
Scientific contact	HOVON Data Center, HOVON, +31 (0)107041560, hdc@erasmusmc.nl

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	03 August 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	26 June 2018
Global end of trial reached?	Yes
Global end of trial date	29 June 2022
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To assess the feasibility, defined as discontinuation rate, of a dose-adapted MPV scheme in MM patients  $\geq 75$  years of age

Protection of trial subjects:

Monitoring and Insurance

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 January 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Netherlands: 240
Worldwide total number of subjects	240
EEA total number of subjects	240

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	212
85 years and over	28

## Subject disposition

### Recruitment

Recruitment details:

All subjects gave written informed consent and were screened according to the inclusion- and exclusion criteria

### Pre-assignment

Screening details:

All subjects gave written informed consent and were screened according to the inclusion- and exclusion criteria

### Period 1

Period 1 title	Overall period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Experimental
-----------	--------------

Arm description:

Experimental

Arm type	Experimental
Investigational medicinal product name	Bortezomib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

IMP: Bortezomib

Duration of each cycle is 35 days (every 5 weeks). Total number of cycles is 9.

dose/day: 1.3 mg/m<sup>2</sup>

Route of administration: s.c.

days of administration: 1, 8, 15, 22

Investigational medicinal product name	Melphalan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

day 1-4 for a maximum of 9 cycles

6 mg/m<sup>2</sup> milligram(s)/square meter/day

Investigational medicinal product name	Prednisone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

day 1 to 4 for a maximum of 9 cycles

30 mg/m<sup>2</sup> milligram(s)/square meter/ day

<b>Number of subjects in period 1</b>	Experimental
Started	240
Completed	130
Not completed	110
Adverse reactions	39
At patient's request	24
other	15
Lack of efficacy	32

## Baseline characteristics

### Reporting groups

Reporting group title	Overall period
-----------------------	----------------

Reporting group description: -

Reporting group values	Overall period	Total	
Number of subjects	240	240	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	212	212	
85 years and over	28	28	
Age continuous			
Units: years			
median	79		
full range (min-max)	75 to 91	-	
Gender categorical			
Units: Subjects			
Female	116	116	
Male	124	124	

## End points

### End points reporting groups

Reporting group title	Experimental
Reporting group description:	
Experimental	

### Primary: primary endpoint

End point title	primary endpoint <sup>[1]</sup>
End point description:	

End point type	Primary
End point timeframe:	
see publication	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: See attached chart/documents for results

<b>End point values</b>	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	201			
Units: whole	201			

<b>Attachments (see zip file)</b>	List of reported non-SAE's/nonsaedata123-13Jan2023.pdf Statistical data section from publication/Ho123 publicatie.pdf List of reported SAE's/saedata123-13Jan2023.pdf
-----------------------------------	---

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

AEs will be reported from the first study-related procedure until 30 days following the last dose of any drug from the protocol treatment schedule or until the start of subsequent systemic therapy for the disease under investigation, if earlier.

Adverse event reporting additional description:

Adverse events occurring after 30 days should also be reported if considered at least possibly related to the investigational medicinal product by the investigator.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	CTCAE
-----------------	-------

Dictionary version	4
--------------------	---

### Reporting groups

Reporting group title	Experimental
-----------------------	--------------

Reporting group description: -

Serious adverse events	Experimental		
Total subjects affected by serious adverse events			
subjects affected / exposed	132 / 234 (56.41%)		
number of deaths (all causes)	179		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
AML			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Basal cell carcinoma			
subjects affected / exposed	2 / 234 (0.85%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Multiple myeloma progression			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Oesophagus carcinoma			

subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rectal carcinoma			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal cell carcinoma			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urothelial carcinoma			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Cerebral ischemia			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Collapse(vasovagal episode)			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	2 / 234 (0.85%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Intermittent claudication			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Orthostatic hypotension			



subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ruptured abdominal aneurysm			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vein thrombosis			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Venous thrombosis right leg			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Hip surgery			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Surgery			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Admission pain			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Atypical thoracal/precordial pain			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Backpain				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Disease progression				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Exacerbation pain				
subjects affected / exposed	2 / 234 (0.85%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Fever				
subjects affected / exposed	9 / 234 (3.85%)			
occurrences causally related to treatment / all	8 / 14			
deaths causally related to treatment / all	0 / 0			
Fever, unknown cause				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Malaise				
subjects affected / exposed	4 / 234 (1.71%)			
occurrences causally related to treatment / all	4 / 4			
deaths causally related to treatment / all	0 / 0			
Non-neutropenic fever				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Oedema				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Overall weakness				

subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pain			
subjects affected / exposed	3 / 234 (1.28%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Recurrent bleeding along catheter vena jugularis			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Sudden death NOS			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Reproductive system and breast disorders			
Ovarian cyst			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Aspiration			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
COPD exacerbatie			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dyspnea			

subjects affected / exposed	6 / 234 (2.56%)		
occurrences causally related to treatment / all	3 / 6		
deaths causally related to treatment / all	0 / 0		
Epistaxis			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Exp. COPD			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pleural effusion			
subjects affected / exposed	2 / 234 (0.85%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			
subjects affected / exposed	4 / 234 (1.71%)		
occurrences causally related to treatment / all	2 / 4		
deaths causally related to treatment / all	0 / 0		
Relapse pleural effusion			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	2 / 234 (0.85%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Confusion			

subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Delirium			
subjects affected / exposed	3 / 234 (1.28%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Investigations			
Increased CRP			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Weight loss			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fracture			
subjects affected / exposed	3 / 234 (1.28%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Hip fracture			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Atrial Fibrillation				
subjects affected / exposed	2 / 234 (0.85%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
Cardiac arrest				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	1 / 1			
Cardiac failure				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Congestive heart failure				
subjects affected / exposed	2 / 234 (0.85%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
Decompensatio cordis				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Decompensation cardiac				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Flutter				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Heart failure				
subjects affected / exposed	4 / 234 (1.71%)			
occurrences causally related to treatment / all	2 / 4			
deaths causally related to treatment / all	0 / 0			
Mitralis insufficiency				

subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
NSTEMI			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Right ventricular dysfunction			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
STEMI			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Unstable angina pectoris			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Admission because of dizziness			
subjects affected / exposed	3 / 234 (1.28%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 1		
CVA			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Ischialgie			

subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neurological paralysis			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Polyneuropathy			
subjects affected / exposed	2 / 234 (0.85%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Stroke			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Transient ischemic attack			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anemia			
subjects affected / exposed	5 / 234 (2.14%)		
occurrences causally related to treatment / all	3 / 5		
deaths causally related to treatment / all	0 / 0		
Anemia / thrombocytopenia			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Febrile neutropenia			



subjects affected / exposed	2 / 234 (0.85%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Neutropenic fever			
subjects affected / exposed	3 / 234 (1.28%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	1 / 1		
Thrombopenia			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
(Symtomatic) Anemia			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Constipation			
subjects affected / exposed	4 / 234 (1.71%)		
occurrences causally related to treatment / all	4 / 4		
deaths causally related to treatment / all	0 / 0		
Diarrhea			
subjects affected / exposed	2 / 234 (0.85%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Emesis			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastritis erosive			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders other			

subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Nausea and vomiting			
subjects affected / exposed	3 / 234 (1.28%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Rectal bleeding			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Vomiting and diarrhea			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	2 / 234 (0.85%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Ulcer left foot			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Kidney failure			
subjects affected / exposed	3 / 234 (1.28%)		
occurrences causally related to treatment / all	1 / 6		
deaths causally related to treatment / all	0 / 0		

Pain right kidney area intermittent subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Progressive renal insufficiency subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal failure subjects affected / exposed	2 / 234 (0.85%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Renal insufficiency subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary retention subjects affected / exposed	2 / 234 (0.85%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Backache subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bone pain subjects affected / exposed	2 / 234 (0.85%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Myopathy			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pain back			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pain due to MM			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pain in extremity			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Painfull hip			
subjects affected / exposed	2 / 234 (0.85%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Referred pain right leg			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Airway infection			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Catheter related infection			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cellulitis			

subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Cellulitis of her right leg				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Erysipelas				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastro				
subjects affected / exposed	3 / 234 (1.28%)			
occurrences causally related to treatment / all	2 / 3			
deaths causally related to treatment / all	0 / 0			
Infection				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Infection leg				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Infection pulmonary				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Infection urinarytract				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Infection without focus				

subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Lung infection				
subjects affected / exposed	2 / 234 (0.85%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
Phlebitis infective				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	26 / 234 (11.11%)			
occurrences causally related to treatment / all	25 / 30			
deaths causally related to treatment / all	1 / 2			
Pneumosepsis				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Respiratory infection				
subjects affected / exposed	3 / 234 (1.28%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	5 / 234 (2.14%)			
occurrences causally related to treatment / all	3 / 5			
deaths causally related to treatment / all	0 / 0			
Septic shock				
subjects affected / exposed	1 / 234 (0.43%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection				

subjects affected / exposed	5 / 234 (2.14%)		
occurrences causally related to treatment / all	2 / 5		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	3 / 234 (1.28%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
Viral infection			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Yeast infection			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	4 / 234 (1.71%)		
occurrences causally related to treatment / all	3 / 5		
deaths causally related to treatment / all	0 / 0		
Hyper calcemia			
subjects affected / exposed	4 / 234 (1.71%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Hyperglyceamia			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperkalemia			
subjects affected / exposed	2 / 234 (0.85%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Hyponatremia			

subjects affected / exposed	3 / 234 (1.28%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Experimental		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	215 / 234 (91.88%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Additional description: All combined, see non-SAE chart for details		
subjects affected / exposed	4 / 234 (1.71%)		
occurrences (all)	4		
Vascular disorders			
Vascular disorders			
subjects affected / exposed	17 / 234 (7.26%)		
occurrences (all)	18		
Surgical and medical procedures			
Surgical and medical procedures			
subjects affected / exposed	1 / 234 (0.43%)		
occurrences (all)	2		
General disorders and administration site conditions			
General disorders and administration site conditions	Additional description: All combined, see non-SAE chart for details		
subjects affected / exposed	90 / 234 (38.46%)		
occurrences (all)	127		
Immune system disorders			
Immune system disorders	Additional description: All combined, see non-SAE chart for details		
subjects affected / exposed	3 / 234 (1.28%)		
occurrences (all)	3		
Reproductive system and breast disorders			
Reproductive system and breast disorders	Additional description: All combined, see non-SAE chart for details		
subjects affected / exposed	1 / 234 (0.43%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			



Respiratory, thoracic and mediastinal disorders	Additional description: All combined, see non-SAE chart for details		
subjects affected / exposed	23 / 234 (9.83%)		
occurrences (all)	32		
Psychiatric disorders	Additional description: All combined, see non-SAE chart for details		
Psychiatric disorders	Additional description: All combined, see non-SAE chart for details		
subjects affected / exposed	14 / 234 (5.98%)		
occurrences (all)	18		
Investigations	Additional description: All combined, see non-SAE chart for details		
Investigations	Additional description: All combined, see non-SAE chart for details		
subjects affected / exposed	90 / 234 (38.46%)		
occurrences (all)	294		
Injury, poisoning and procedural complications	Additional description: All combined, see non-SAE chart for details		
Injury, poisoning and procedural complications	Additional description: All combined, see non-SAE chart for details		
subjects affected / exposed	5 / 234 (2.14%)		
occurrences (all)	6		
Cardiac disorders	Additional description: All combined, see non-SAE chart for details		
Cardiac disorders	Additional description: All combined, see non-SAE chart for details		
subjects affected / exposed	18 / 234 (7.69%)		
occurrences (all)	19		
Nervous system disorders	Additional description: All combined, see non-SAE chart for details		
Nervous system disorders	Additional description: All combined, see non-SAE chart for details		
subjects affected / exposed	127 / 234 (54.27%)		
occurrences (all)	211		
Blood and lymphatic system disorders	Additional description: All combined, see non-SAE chart for details		
Blood and lymphatic system disorders	Additional description: All combined, see non-SAE chart for details		
subjects affected / exposed	52 / 234 (22.22%)		
occurrences (all)	92		
Ear and labyrinth disorders	Additional description: All combined, see non-SAE chart for details		
Ear and labyrinth disorders	Additional description: All combined, see non-SAE chart for details		
subjects affected / exposed	2 / 234 (0.85%)		
occurrences (all)	2		
Eye disorders	Additional description: All combined, see non-SAE chart for details		
Eye disorders	Additional description: All combined, see non-SAE chart for details		
subjects affected / exposed	15 / 234 (6.41%)		
occurrences (all)	18		
Gastrointestinal disorders			

Gastrointestinal disorders subjects affected / exposed occurrences (all)	Additional description: All combined, see non-SAE chart for details		
	86 / 234 (36.75%) 143		
Skin and subcutaneous tissue disorders Skin and subcutaneous tissue disorders subjects affected / exposed occurrences (all)	Additional description: All combined, see non-SAE chart for details		
	21 / 234 (8.97%) 23		
Renal and urinary disorders Renal and urinary disorders subjects affected / exposed occurrences (all)	Additional description: All combined, see non-SAE chart for details		
	21 / 234 (8.97%) 25		
Musculoskeletal and connective tissue disorders Musculoskeletal and connective tissue disorders subjects affected / exposed occurrences (all)	Additional description: All combined, see non-SAE chart for details		
	45 / 234 (19.23%) 68		
Infections and infestations Infections and infestations subjects affected / exposed occurrences (all)			
	60 / 234 (25.64%) 76		
Metabolism and nutrition disorders Metabolism and nutrition disorders subjects affected / exposed occurrences (all)	Additional description: All combined, see non-SAE chart for details		
	46 / 234 (19.66%) 70		

**More information**

**Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 December 2015	Expansion of study by 100 patients
26 February 2016	Update to the protocol due to an error in Appendix A

Notes:

---

**Interruptions (globally)**

Were there any global interruptions to the trial? No

**Limitations and caveats**

None reported